Compare PRAA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAA | PLRX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 2615 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.0M | 69.7M |
| IPO Year | 2002 | 2020 |
| Metric | PRAA | PLRX |
|---|---|---|
| Price | $18.86 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | ★ 374.0K | 360.8K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $1,201,837,000.00 | N/A |
| Revenue This Year | $8.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.70 | ★ N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $10.25 | $1.02 |
| 52 Week High | $22.55 | $1.95 |
| Indicator | PRAA | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 45.29 |
| Support Level | $18.34 | $1.02 |
| Resistance Level | $21.39 | $1.37 |
| Average True Range (ATR) | 0.91 | 0.04 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 42.31 | 18.18 |
PRA Group Inc is a specialty finance company engaged in the purchase, collection, and management of nonperforming loan portfolios. The majority of the loans it purchases are from credit originators who have chosen not to pursue, or have been unsuccessful in collecting, the full balance owed to them (Core accounts). To a lesser extent, the company also purchases loans in situations where the customer is involved in a bankruptcy or similar proceeding (Insolvency accounts). As part of an ancillary business, it also purchases and provides fee-based services for class action claims recoveries in the U.S. The company has two operating and reportable segments, comprised of its U.S. and European businesses. The majority of its revenue is generated from the United States.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.